Harvard Bioscience, Inc. is a developer, manufacturer, and seller of technologies, products, and services for life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company operates through two main product families: Cellular and Molecular (CMT) and Preclinical. The CMT family supports molecular, cellular, organ, and organoid technologies, featuring electroporation instruments, amino acid analyzers, spectrophotometers, syringe pumps, and microelectrode array systems. The Preclinical family provides platforms for physiological data collection and safety testing, including telemetry systems, behavioral products, respiratory solutions, and inhalation systems. The company serves academic institutions, government laboratories, pharmaceutical and biotechnology companies, and contract research organizations globally, with operations in the United States, Europe, and China. Founded in 1901 as Harvard Apparatus, the company was incorporated in 2000 and acquired Data Sciences International in 2018 to expand its preclinical portfolio. Key brands include Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Instruments & Supplies Homepage harvardbioscience.com
Sector Healthcare IR page investor.harvardbioscience.com
Tags
electrophysiology, preclinical testing, organoid research, bioproduction, telemetry systems, spectrophotometry, amino acid analysis, microelectrode arrays, behavioral monitoring, respiratory testing, Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, Data Sciences International, DSI, Panlab, Hugo Sachs, Buxco, MeshMEA, SoHo, VivaMars, Ponemah, ALI MEA, AcadeMEA, Incub8, Ultrospec 7500, Biochrom Ultrospec 30, Biochrom Ultrospec 35c, Biowave 3, Biochrom Bio 31+, Biochrom Bio 30+
Press page —

Metrics

Valuation  
Market cap $ 36.219M
Market cap (USD) $ 36.219M
P/E -3.86
PEG —
P/BV 7.09
P/S 0.41
P/OCF -53.18
P/FCF -11.42
Dividend yield —
Turnover / mcap —
Returns  
ROE -147.1%
ROI -114.3%
ROIC -73.5%
Profit margin -65.5%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 727.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 3
Quality score -66.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Revenue 86.55M 94.135M 112.25M 113.335M 118.904M 102.1M 116.176M 120.774M 101.882M 104.521M 108.664M 108.663M 105.171M 111.171M 108.864M 108.179M 85.772M 88.049M 83.407M 76.181M 67.431M 91.485M 86.197M 56.344M 40.005M 30.575M 26.178M
Net profit -56.7M -12.405M -3.415M -9.516M -288K -7.81M -4.687M -2.922M -865K -4.307M -19.039M 2.355M -1.83M 2.37M 3.812M 19.015M 7.233M 1.673M -1.354M -2.341M -31.877M 2.329M 4.26M 737.327K -5.208M -49.87M -29.42M
Free cash flow 5.471M -1.204M 12.24M -438K 67K 8.179M 6.829M 1.898M — — — — — — — — 15.133M 7.894M 10.603M 5.97M 4.095M 8.427M 678.649K -507.266K 2.256M 1.516M 2.594M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Share price 0.67 2.11 5.35 2.77 7.05 4.29 3.05 3.18 3.3 3.05 3.47 5.67 4.7 4.06 5.97 3.63 3.75 2.46 4.51 5.05 — — — — — — —
Price performance 12m -0.68 -0.61 0.93 -0.61 0.64 0.41 -0.04 -0.04 0.08 -0.12 -0.39 0.21 0.16 -0.32 0.64 -0.03 0.52 -0.45 -0.11 — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 15.7M 16.2M 21.5M 20.7M 17.8M 21.8M 16.7M 16.1M 14.9M 16M
↳ YoY growth -10.3% +3.1% +32.2% -3.5% -14.2% +22.9% -23.5% -3.6% -7.7% +7.9%
↳ 5y CAGR +0.9% +2.5% +9.1% +5.1% +0.2% +6.8% +0.6% -5.6% -6.4% -2.0%
Borrowings, current (USD) — — 2.4M 3.2M 2M 3.52M 4.09M 6.14M 37.4M 0.00
Borrowings, non-current (USD) 11.4M 8.98M 58.8M 46.9M 46.3M 45.1M 43M 30.7M 0.00 35.9M
Lease liabilities (USD) — — 0.00 10.6M 9.59M 8.63M 7.42M 6.21M 7.54M 8.41M
Cash and deposits (USD) 5.6M 5.73M 8.17M 8.34M 8.32M 7.82M 4.51M 4.28M 4.11M 8.61M
Intangible assets (USD) 17.5M 16M 44.5M 38.4M 33.2M 27.4M 21M 16M 11.1M 7.64M
Right-of-use assets (USD) — — 9.4M 8.46M 7.76M 6.9M 5.82M 4.77M 6.13M 7.17M
Net debt (borrowings + leases - cash) (USD) 5.78M 3.25M 50.6M 52.4M 49.6M 49.4M 50M 38.8M 40.8M 35.7M
Cash flow detail
Operating cash flow (USD) 5.38M 1.06M 2.88M 8.05M 9.33M 1.26M 1.15M 14M 1.44M 6.73M
Purchases of property, plant and equipment (USD) — -890,000 -986,000 -1.22M -1.15M -1.2M -1.59M -1.79M -2.64M -1.26M
Purchases of intangible assets (USD) — — — — -250,000 -150,000 0.00 -523,000 -619,000 -605,000
Change in receivables (cash effect) (USD) 566,000 196,000 -2.79M 468,000 3.11M -4.29M 4.78M 810,000 974,000 -934,000
Change in inventories (cash effect) (USD) 1.25M -548,000 2.55M 3.26M 413,000 -5.86M 252,000 1.52M -64,000 2.95M
Change in payables (cash effect) (USD) — — 1.59M -2.05M 511,000 2.45M -1.4M 555,000 -1.79M 2.3M
Interest paid (cash effect) (USD) -620,000 -686,000 -4.99M -5.5M -4.88M -1.58M -2.31M -3.8M -3.24M -3.6M
Income taxes paid (cash effect) (USD) -928,000 13,000 -98,000 -374,000 -416,000 -577,000 -534,000 -207,000 159,000 98,000
Share-based compensation (USD) 3.5M 3.5M 3.04M 3.03M 3.65M 4.17M 4.41M 5M 4.34M 1.86M
Operating cash flow before change in receivables (USD) 4.82M 861,000 5.68M 7.58M 6.23M 5.56M -3.63M 13.2M 466,000 7.66M
Free cash flow (OCF - PPE - intangibles) (USD) — 167,000 1.9M 6.83M 8.18M -83,000 -438,000 11.7M -1.82M 4.87M
Income detail
Research and development expense (USD) 5.39M 5.65M 11M 10.7M 8.69M 10.8M 12.3M 11.8M 10.4M 8.83M
↳ 5y CAGR -0.2% -5.1% +21.5% +17.0% +6.2% +14.9% +16.9% +1.4% -0.6% +0.3%
Total comprehensive income (USD) -9.08M 5.12M -5.78M -3.84M -8.19M 2.75M -14.5M -2.55M -13.9M -52.7M
Comprehensive income to owners (USD) -9.08M 5.12M -5.78M -3.84M -8.19M 2.75M -14.5M -2.55M -13.9M -52.7M
Provision for credit losses (USD) 309,000 -109,000 25,000 288,000 17,000 -4,000 62,000 29,000 60,000 16,000
Credit cost ratio (credit losses / average receivables) (%) 1.9% 0.7% 0.1% 1.4% 0.1% 0.0% 0.3% 0.2% 0.4% 0.1%
Reported Mar 17, 2017 Mar 18, 2019 Mar 16, 2020 Mar 16, 2020 Mar 11, 2022 Mar 11, 2022 Mar 9, 2023 Mar 7, 2024 Mar 14, 2025 Mar 13, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Corporate Presentation

The Company from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. A copy of the Company’s current corporate slide presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference.

· Third Quarter 2026 Revenue Growth of 8% Year Over Year to $22.2 Million

· Reaffirms Full Year 2026 Revenue Guidance of 3%-5% Year Over Year Growth

HOLLISTON, Mass., November 10, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the third quarter ended September 30, 2026.

“We delivered our second consecutive quarter of strong year over year growth with an 8% topline increase in the third quarter,” said John Duke, President and Chief Executive Officer. “We saw solid double-digit revenue growth to CROs and customers in China, driven by sales of our products for organoids, respiratory, and fluidics products. Our revamped sales and marketing teams are delivering encouraging results, and Project Viking remains on track for completion by the end of the first quarter in 2027.

November 4, 2026

PDF Version

HOLLISTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Chief Financial Officer, will participate in Canaccord Genuity’s MedTech, Diagnostics, and Digital Health and Services Forum on November 11th, 2026.

Management will participate in one-on-one meetings, and John Duke will present on the “Emerging Tools for Research and Biopharma Use Cases” panel at 9:30am ET.

About Harvard Bioscience

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

Prompts

Harvard Bioscience, Inc. (ticker HBIO), listed in United States.

ETFs Holding Harvard Bioscience, Inc.

ETF Weight in ETF Shares Market value As of
DFSU 0.00% 1,902 $ 17.527K Nov 12, 2026
DXUV 0.00% 1,229 $ 11.325K Nov 12, 2026
DFAS 0.00% 1,624 $ 14.965K Nov 12, 2026
DCOR 0.00% 928 $ 8,551.52 Nov 12, 2026
DFAC 0.00% 1,029 $ 9,482.24 Nov 12, 2026